Population Pharmacokinetics of Tralokinumab in Adult Subjects With Moderate to Severe Atopic Dermatitis

Tralokinumab is the first biologic therapy for moderate‐to‐severe atopic dermatitis (AD) that specifically neutralizes interleukin‐13 activity, a key driver of AD signs and symptoms. Tralokinumab is a human immunoglobulin G4 monoclonal antibody administered subcutaneously every 2 weeks (with possibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Soehoel, Anders, Larsen, Malte Selch, Timmermann, Stine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796478/
https://www.ncbi.nlm.nih.gov/pubmed/35671038
http://dx.doi.org/10.1002/cpdd.1113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796478/
https://www.ncbi.nlm.nih.gov/pubmed/35671038
http://dx.doi.org/10.1002/cpdd.1113

Ejemplares similares